Bi104 is a microbiome-modifying biologic designed to diversify and modulate the gut microflora and metabolite profile.
AB-Biotics recently appointed to the IPA board of directors. What opportunities and future developments? We discussed this with Miquel Bonachera.
The findings of a recent study shed light on how the microbiota impacts cholesterol levels. They may also inform microbial-based interventions against high cholesterol.
Industry
Sponsored by
Join SynBalance at Vitafoods Europe 2024, held at Palexpo, Switzerland from May 14th to May 16th.
The findings of a recent study suggest that L. johnsonii or its metabolite IPA could be used as a microbial-based approach to improve a person’s response to immunotherapy.
The intersection of gaming and science has birthed an innovative approach to scientific research and public engagement.
This unprecedented partnership signifies a concerted effort to address pressing microbiome-related challenges and advance health equity worldwide.
Biofarma Group has consolidated its expertise in the formulation of dietary supplements aimed at cardiometabolic well-being.
The findings of a recent study suggest that specific microbial signatures are associated with accelerated biological aging.
The findings of a recent study suggest that 2MBC exacerbates the susceptibility to thrombosis and may explain why people with COVID-19 are at increased thrombotic risk.
